Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Marshall, Alison DCunningham, Evan B
Nielsen, Stine
Aghemo, Alessio
Alho, Hannu
Backmund, Markus
Bruggmann, Philip
Dalgard, Olav
Seguin-Devaux, Carole
Flisiak, Robert
Foster, Graham R
Gheorghe, Liana
Goldberg, David
Goulis, Ioannis
Hickman, Matthew
Hoffmann, Patrick
Jancorienė, Ligita
Jarcuska, Peter
Kåberg, Martin
Kostrikis, Leondios G
Makara, Mihály
Maimets, Matti
Marinho, Rui Tato
Matičič, Mojca
Norris, Suzanne
Ólafsson, Sigurður
Øvrehus, Anne
Pawlotsky, Jean-Michel
Pocock, James
Robaeys, Geert
Roncero, Carlos
Simonova, Marieta
Sperl, Jan
Tait, Michele
Tolmane, Ieva
Tomaselli, Stefan
van der Valk, Marc
Vince, Adriana
Dore, Gregory J
Lazarus, Jeffrey V
Grebely, Jason
Issue Date
2018-02
Metadata
Show full item recordCitation
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe 2018, 3 (2):125 The Lancet Gastroenterology & HepatologyAbstract
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.Description
To access publisher's full text version of this article click on the hyperlink belowAdditional Links
http://linkinghub.elsevier.com/retrieve/pii/S2468125317302844Rights
Archived with thanks to The Lancet Gastroenterology & Hepatologyae974a485f413a2113503eed53cd6c53
10.1016/S2468-1253(17)30284-4
Scopus Count
Collections